Silencing Receptor EphA2 Enhanced Sensitivity to Lipoplatin™ in Lung Tumor and MPM Cells

Cancer Investigation 2016 July 20 [Epub ahead of print] [Link] Lee HY, Mohammed KA, Goldberg EP, Kaye F4, Nasreen N Abstract Receptor EphA2 is overexpressed in lung cancer and malignant pleural mesothelioma (MPM) which promote tumorogenesis. Lipoplatin™, a new liposomal cisplatin formulation, is used against resistant tumors. Use of cisplatin-based drugs leads to unacceptable toxicities.…

Read More

Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two cases

Lung Cancer (Amsterdam, Netherlands) 2016 July 14 [Epub ahead of print] [Link] Metaxas Y, Cathomas R, Mark M, von Moos R Abstract Malignant mesothelioma is an aggressive disease with dismal prognosis despite multimodal treatment including chemotherapy, surgery and radiotherapy. At progression it is possible to provide systemic second-line treatment but its effects are limited. Herein…

Read More

Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma

Oncotarget 2016 July 18 [Epub ahead of print] [Link] Carbone M, Shimizu D, Napolitano A, Tanji M, Pass HI, Yang H, Pastorino S. Abstract The differential diagnosis between pleural malignant mesothelioma (MM) and lung cancer is often challenging. Immunohistochemical (IHC) stains used to distinguish these malignancies include markers that are most often positive in MM…

Read More

A Biphasic Pleural Tumor with Features of an Epithelioid and Small Cell Mesothelioma: Morphologic and Molecular Findings

Case Reports in Pathology [Epub 2016 June 15] [Link] Hackman S, Hammer RD, Layfield L Abstract Abstract Malignant mesotheliomas are generally classified into epithelioid, sarcomatoid, desmoplastic, and biphasic types with rare reports of a small cell form. These small cell variants display some morphologic overlap with desmoplastic small round cell tumors (DSRCTs) which generally occur…

Read More

Establishment of anti-mesothelioma monoclonal antibodies

BMC Research Notes [Epub ahead of print] [Link] Mizutani N, Abe M, Matsuoka S, Kajino K, Wakiya M, Ohtsuji N, Hatano R, Morimoto C, Hino O. Abstract BACKGROUND: Mesotheliomas are aggressive, therapy-resistant tumors that are predicted to increase in incidence at least until 2020. The prognosis of patients with mesothelioma is generally poor because they…

Read More

KCa1.1, a calcium-activated potassium channel subunit alpha 1, is targeted by miR-17-5p and modulates cell migration in malignant pleural mesothelioma

Molecular Cancer 2016 June 1 [Link] Cheng YY, Wright CM, Kirschner MB, Williams M, Sarun KH, Sytnyk V, Leshchynska I, Edelman JJ, Vallely MP, McCaughan BC, Klebe S, van Zandwijk N, Lin RC, Reid G. Abstract BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive, locally invasive, cancer elicited by asbestos exposure and almost invariably a…

Read More

Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization-array

Human Pathology 2016 May 13 [Epub ahead of print] [Link] Chirac P, Maillet D, Leprêtre F, Isaac S, Glehen O, Figeac M, Villeneuve L, Péron J, Gibson F, Galateau-Sallé F, Gilly FN, Brevet M Abstract Malignant peritoneal mesotheliomas (MPM) are rare, accounting for approximately 8% of cases of mesothelioma in France. We performed comparative genomic…

Read More

Massive chest wall resection and reconstruction for malignant disease.

Onco Targets and Therapy 2016 April 19 [Epub ahead of print] [Link] Foroulis CN, Kleontas AD, Tagarakis G, Nana C, Alexiou I, Grosomanidis V, Tossios P, Papadaki E, Kioumis I, Baka S, Zarogoulidis P, Anastasiadis K. Abstract OBJECTIVE: Malignant chest wall tumors are rare neoplasms. Resection with wide-free margins is an important prognostic factor, and…

Read More